Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations

Abstract excerpt

Epidermal growth factor receptor ( EGFR) mutation is one of the key oncogenic mutations in non-small-cell lung cancer with adenocarcinoma histology. Exon 19 deletions and exon 21 L858R substitutions account for 90%, while EGFR exon 20 insertions constitute 4–10% of EGFR mutations and are the third most prevalent activating EGFR mutations. EGFR exon 20 insertions are associated with decreased sensitivity to EGFR...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colorectal Cancer Treatments and Studies
• Share to Lung Cancer Research Studies
• Share to Lung Cancer Treatments and Mutations